Program
EP4 Receptor Antagonist YY001
Also written as “Rcombinant botulinum neurotoxin type A for injection (YY001)”, “YY001” and “Recombinant botulinum toxin type A for injection (YY001)”.
Its studies are led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Claruvis Pharmaceutical | 52 open or running | phase 3since Jul 7, 2024 | Feb 15, 2023 | Jun 1, 2027phase 3 · NCT07478822 |
| Shanghai Yuyao Biotech | 10 open or running | phase 1since Jan 17, 2024 | Jan 17, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 15, 2023First study: phase 2 study in Moderate to Severe Glabellar LinesNew to Chongqing Claruvis PharmaceuticalChongqing Claruvis Pharmaceutical · NCT05743634 · 140 enrolled · China
- Jan 17, 2024Shanghai Yuyao Biotech’s first study: phase 1 study in Advanced Solid TumorNew to Shanghai Yuyao BiotechShanghai Yuyao Biotech · NCT06228846 · 16 enrolled · China
- Jul 7, 20242 phase 3 studies in Moderate to Severe Glabellar LinesChongqing Claruvis Pharmaceutical · NCT06583486, NCT06499688
- Jan 14, 2025Phase 3 study in Upper Limb SpasticityChongqing Claruvis Pharmaceutical · NCT06783114 · 254 planned · China
- Mar 11, 2026Phase 3 study in Upper Limb SpasticityChongqing Claruvis Pharmaceutical · NCT07478822 · 300 planned · China
Ahead
- Jun 1, 2027Primary completion: phase 3 study in Upper Limb SpasticityChongqing Claruvis Pharmaceutical · NCT07478822
TargetBeta
“An orally bioavailable small molecule antagonist of the prostaglandin E2 receptor EP4 subtype (PTGER4; EP4), ”NCIt, by rule
Other programs on PTGER4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| BMS-986310rule | Ono Pharmaceutical | phase 3 | 6 |
| EP2/EP4/DP1 Antagonist OKN4395rule | epkin | phase 1 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07478822Upper Limb Spasticity · China | 3 | Recruiting | Chongqing Claruvis Pharmaceutical | Jun 1, 2027 | 300 |
| NCT06783114Upper Limb Spasticity · China | 3 | Recruiting | Chongqing Claruvis Pharmaceutical | Sep 30, 2026 | 254 |
| NCT06583486Moderate to Severe Glabellar Lines · China | 3 | Completed | Chongqing Claruvis Pharmaceutical | Aug 25, 2025 | 488 |
| NCT06499688Moderate to Severe Glabellar Lines · China | 3 | Completed | Chongqing Claruvis Pharmaceutical | Mar 29, 2024 | 529 |
| NCT06228846Advanced Solid Tumor · China | 1 | Completed | Shanghai Yuyao Biotech | Apr 30, 2024 | 16 |
| NCT05743634Moderate to Severe Glabellar Lines · China | 2 | Completed | Chongqing Claruvis Pharmaceutical | Feb 13, 2023 | 140 |
How it is read
Names in the registry
- “Rcombinant botulinum neurotoxin type A for injection (YY001)”, 2 entries
- “YY001”, 2 entries
- “Recombinant botulinum toxin type A for injection (YY001)”, 1 entry
- “Recombinant Botulinum Toxin Type A for injection (YY001)”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.